Lexeo Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lexeo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2022 to 2023.
  • Lexeo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$21.2M, a 58% decline year-over-year.
  • Lexeo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$77.2M, a 21.2% decline year-over-year.
  • Lexeo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$66.4M, a 12% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$66.4M -$7.12M -12% Jan 1, 2023 Dec 31, 2023 10-Q 2024-08-12
2022 -$59.3M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.